Inflammation as a Cardiovascular Risk Factor: Are We Ready for Anti-Inflammatory Therapy?

Introduction

Atherosclerosis is now recognized as a complex, chronic inflammatory disease rather than a simple disorder of lipid accumulation within the arterial wall. Although elevated cholesterol levels remain a major contributor to disease development, contemporary research has demonstrated that the initiation, progression, and clinical complications of atherosclerosis are driven by a dynamic interplay between lipid metabolism, vascular inflammation, immune activation, and thrombosis. This paradigm shift was notably advanced by the seminal work of Ross in 1999, which established atherosclerosis as an inflammatory disease characterized by continuous interactions between endothelial cells, circulating leukocytes, vascular smooth muscle cells, and inflammatory mediators.

The pathogenesis of atherosclerosis begins with endothelial dysfunction, a process triggered by traditional cardiovascular risk factors such as hyperlipidemia, hypertension, diabetes mellitus, smoking, obesity, and chronic kidney disease. Under normal conditions, the endothelium maintains vascular homeostasis by regulating vascular tone, preventing thrombosis, and limiting inflammatory cell adhesion. However, exposure to metabolic and hemodynamic stressors impairs endothelial function, resulting in increased vascular permeability, reduced nitric oxide bioavailability, oxidative stress, and expression of adhesion molecules that facilitate leukocyte recruitment.

Low density lipoprotein cholesterol particles subsequently penetrate the dysfunctional endothelial barrier and accumulate within the arterial intima. These lipoproteins undergo oxidative and enzymatic modifications that transform them into potent inflammatory stimuli. Modified lipoproteins activate endothelial cells and attract circulating monocytes, which migrate into the vessel wall and differentiate into macrophages. These macrophages engulf oxidized lipoproteins and become lipid laden foam cells, forming the earliest visible atherosclerotic lesions known as fatty streaks.

As the disease progresses, the arterial wall becomes the site of persistent immune activation. Macrophages, T lymphocytes, dendritic cells, and other inflammatory cells release a variety of cytokines, chemokines, and growth factors that perpetuate inflammation and drive plaque development. Key inflammatory mediators including interleukin 1 beta, interleukin 6, tumor necrosis factor alpha, and other cytokine networks contribute to endothelial injury, smooth muscle cell migration, extracellular matrix remodeling, and further recruitment of inflammatory cells. These processes transform early lesions into complex atherosclerotic plaques with fibrous caps, lipid rich necrotic cores, and varying degrees of calcification.

Importantly, atherosclerosis is not a static condition. Plaques continuously undergo remodeling influenced by inflammatory activity within the vessel wall. Some plaques remain relatively stable and cause symptoms primarily through progressive luminal narrowing. Others become vulnerable to rupture due to ongoing inflammation, degradation of structural proteins, thinning of the fibrous cap, and enlargement of the necrotic core. Plaque rupture or erosion exposes highly thrombogenic material to circulating blood, triggering platelet activation and thrombus formation. These thrombotic events are responsible for many acute cardiovascular syndromes, including myocardial infarction, ischemic stroke, and sudden cardiac death.

The recognition of inflammation as a central driver of atherosclerotic disease has important clinical implications. Despite substantial advances in lipid lowering therapy, antihypertensive treatment, antithrombotic strategies, and lifestyle modification, many patients continue to experience cardiovascular events. This phenomenon is often referred to as residual cardiovascular risk. While a portion of this residual risk remains attributable to inadequately controlled lipoprotein abnormalities such as elevated low density lipoprotein cholesterol, apolipoprotein B, or lipoprotein(a), additional contributors include diabetes mellitus, obesity, chronic kidney disease, smoking, hypertension, thrombogenic factors, and suboptimal medication adherence. Increasing evidence suggests that persistent vascular inflammation represents another major component of this residual risk burden.

The concept of residual inflammatory risk has attracted considerable attention in cardiovascular medicine. Patients may achieve recommended lipid targets yet continue to demonstrate elevated inflammatory biomarkers and experience recurrent cardiovascular events. This observation has prompted investigations into whether targeting inflammation directly can provide cardiovascular benefit beyond traditional risk factor modification.

Among available inflammatory biomarkers, high sensitivity C reactive protein has emerged as the most widely utilized clinical measure of systemic inflammation and residual inflammatory risk. Synthesized by the liver primarily in response to interleukin 6 signaling, hsCRP serves as an indirect marker of inflammatory activity throughout the body. Numerous epidemiological studies have demonstrated that elevated hsCRP levels are associated with an increased risk of future cardiovascular events in both primary prevention and secondary prevention populations. Elevated hsCRP has been linked to higher rates of myocardial infarction, ischemic stroke, peripheral arterial disease, and cardiovascular mortality, even among individuals receiving statin therapy.

However, the clinical interpretation of hsCRP requires careful consideration. Although elevated hsCRP levels may identify individuals at increased cardiovascular risk, the biomarker itself does not establish a specific diagnosis or identify the precise source of inflammation. High sensitivity C reactive protein is influenced by a wide range of conditions including acute infections, chronic inflammatory diseases, trauma, recent surgical procedures, malignancy, and obesity. Consequently, an elevated hsCRP value should not automatically prompt anti inflammatory pharmacotherapy without a thorough clinical evaluation. To improve accuracy, measurements should ideally be obtained when patients are free from acute illness and repeated when necessary to confirm persistent elevation.

Recent clinical trials have further strengthened the inflammatory hypothesis of atherosclerosis by demonstrating that targeted anti inflammatory therapies can reduce cardiovascular event rates independent of lipid lowering effects. These findings support the notion that inflammation is not merely a marker of disease activity but an active participant in atherogenesis and plaque destabilization. Nevertheless, questions remain regarding patient selection, optimal biomarkers, therapeutic targets, cost effectiveness, and long term safety of inflammation directed treatments.

As understanding of atherosclerosis continues to evolve, it is increasingly clear that effective cardiovascular prevention requires a comprehensive approach that extends beyond cholesterol management alone. Future strategies must address the interconnected contributions of dyslipidemia, inflammation, thrombosis, metabolic dysfunction, and vascular biology. Recognizing atherosclerosis as a chronic inflammatory disease has fundamentally transformed cardiovascular medicine and provides new opportunities for risk stratification, therapeutic innovation, and personalized patient care.

Mechanistic Rationale

Inflammation is now recognized as a fundamental contributor to the development, progression, and clinical complications of atherosclerotic cardiovascular disease. While dyslipidemia has traditionally been viewed as the primary driver of atherosclerosis, extensive experimental, translational, and clinical evidence has demonstrated that inflammatory pathways play a critical role throughout every stage of the atherothrombotic process. The interaction between lipid accumulation, vascular injury, immune activation, and thrombosis creates a self perpetuating cycle that promotes plaque progression and increases the likelihood of acute cardiovascular events such as myocardial infarction and ischemic stroke.

The atherogenic process begins with endothelial dysfunction, a condition characterized by impaired vascular homeostasis and reduced protective endothelial activity. Endothelial cells exposed to cardiovascular risk factors including elevated low density lipoprotein cholesterol, hypertension, cigarette smoke, hyperglycemia, oxidative stress, and disturbed blood flow undergo phenotypic changes that promote inflammation. These activated endothelial cells increase the expression of adhesion molecules such as vascular cell adhesion molecule 1 and intercellular adhesion molecule 1, facilitating the recruitment and attachment of circulating monocytes and other immune cells to the vascular wall.

Following adhesion, monocytes migrate into the subendothelial space, where they differentiate into macrophages and begin to ingest retained and oxidized lipoproteins. Progressive lipid accumulation transforms these macrophages into foam cells, which are a hallmark of early atherosclerotic lesions. Foam cells are not merely passive lipid storage sites. Rather, they function as highly active inflammatory cells that secrete cytokines, chemokines, growth factors, and proteolytic enzymes that amplify local immune responses. These mediators recruit additional inflammatory cells, stimulate smooth muscle cell migration and proliferation, and contribute to the enlargement and progression of atherosclerotic plaques.

As the disease advances, the inflammatory environment within the arterial wall becomes increasingly complex. Macrophages, dendritic cells, T lymphocytes, mast cells, and other immune populations interact through intricate signaling networks that sustain chronic vascular inflammation. This persistent inflammatory state promotes extracellular matrix degradation, weakens the fibrous cap that overlies the lipid rich necrotic core, and increases plaque vulnerability. Vulnerable plaques are particularly dangerous because they are prone to rupture or erosion, events that expose thrombogenic material to circulating blood and trigger acute thrombus formation.

Among the inflammatory pathways implicated in atherosclerosis, the nucleotide binding oligomerization domain like receptor family pyrin domain containing 3 inflammasome has emerged as one of the most extensively studied. The NLRP3 inflammasome functions as a critical component of the innate immune system and serves as a molecular sensor of cellular stress and danger signals. Within atherosclerotic plaques, cholesterol crystals, oxidized lipids, and other stress related stimuli activate the NLRP3 inflammasome, leading to the activation of caspase 1 and subsequent maturation of pro inflammatory cytokines, particularly interleukin 1 beta.

Interleukin 1 beta occupies a central position in the inflammatory cascade associated with atherosclerotic disease. Once released, it promotes further immune cell recruitment, endothelial activation, and vascular inflammation. Importantly, interleukin 1 beta also stimulates the production of interleukin 6, a multifunctional cytokine with broad systemic effects. Interleukin 6 subsequently acts on the liver to induce the synthesis of acute phase reactants, including C reactive protein. This sequence of biological events, often referred to as the IL 1 beta to IL 6 to C reactive protein axis, provides a mechanistically coherent framework linking local arterial inflammation with measurable circulating biomarkers and clinically relevant cardiovascular outcomes.

The significance of this pathway extends beyond biological plausibility. Elevated levels of inflammatory biomarkers, particularly high sensitivity C reactive protein, have consistently been associated with increased cardiovascular risk across diverse populations. These observations have strengthened the concept that residual inflammatory risk may persist even after optimal management of traditional risk factors such as low density lipoprotein cholesterol. Consequently, inflammation has become an important therapeutic target in contemporary cardiovascular medicine, complementing established lipid lowering strategies.

Despite the compelling evidence supporting the role of inflammation in atherosclerosis, it is important to maintain a balanced perspective regarding its clinical significance. Inflammation should be viewed as a major contributor to cardiovascular risk rather than the sole determinant of disease progression. Atherosclerosis is a multifactorial condition influenced by genetic predisposition, lipid abnormalities, metabolic dysfunction, hypertension, thrombosis, environmental exposures, and lifestyle factors. These processes interact in complex ways, and successful cardiovascular risk reduction often requires simultaneous modification of multiple pathways.

Furthermore, the presence of anti inflammatory activity alone does not guarantee cardiovascular benefit. Clinical experience has demonstrated that some anti inflammatory therapies fail to reduce cardiovascular events despite effectively suppressing inflammatory biomarkers. Several factors may explain these outcomes. The targeted pathway may not represent a critical driver of atherosclerotic progression in a given population. The study population may not exhibit sufficient inflammatory activity to derive meaningful benefit. Alternatively, treatment related adverse effects such as infection risk, immunosuppression, or off target toxicity may offset any potential cardiovascular advantages.

These considerations highlight the importance of precision medicine approaches in cardiovascular prevention. Future therapeutic strategies will likely require more accurate identification of patients with elevated residual inflammatory risk, improved biomarker guided patient selection, and interventions that specifically target biologically relevant inflammatory pathways without introducing unacceptable safety concerns. The success of such approaches depends on a deeper understanding of the interplay between lipid metabolism, innate immunity, vascular biology, and thrombosis.

In summary, inflammation plays a pivotal role in the initiation, progression, and clinical manifestations of atherosclerotic cardiovascular disease. The NLRP3 inflammasome and the downstream IL 1 beta, IL 6, and C reactive protein signaling cascade provide a biologically compelling link between vascular injury and adverse cardiovascular outcomes. However, inflammation represents one component of a broader and highly interconnected disease process. Continued investigation into inflammatory mechanisms and targeted therapies will be essential for refining cardiovascular risk reduction strategies and improving long term patient outcomes.

Evidence From Major Trials

CANTOS

CANTOS tested canakinumab, a monoclonal antibody targeting IL-1β, in patients with prior myocardial infarction and hsCRP of at least 2 mg/L despite standard care. Canakinumab reduced the composite of cardiovascular death, myocardial infarction, or stroke, with the clearest signal at the 150 mg dose (Ridker et al., 2017). Because LDL cholesterol was not reduced, the trial provided important proof-of-concept that targeting inflammation can lower ischemic event rates through a pathway distinct from lipid lowering.

CANTOS also highlighted practical limitations. Canakinumab increased fatal infection or sepsis risk and remains costly. It is not a routine cardiovascular prevention therapy. Its most important contribution is mechanistic validation of the inflammatory hypothesis, not broad clinical implementation.

COLCOT

COLCOT randomized patients within 30 days after myocardial infarction to colchicine 0.5 mg daily or placebo in addition to standard therapy. Colchicine reduced a composite endpoint that included cardiovascular death, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to revascularization (Tardif et al., 2019). The trial supported the concept that low-dose colchicine may reduce recurrent ischemic events after myocardial infarction in selected patients.

However, COLCOT should not be interpreted as a mandate for all post-MI patients. Exclusions included clinically important renal or hepatic disease, neuromuscular disease, chronic diarrhea, inflammatory bowel disease, and colchicine intolerance. These exclusions matter in routine practice, where polypharmacy and chronic kidney disease are common.

LoDoCo2

LoDoCo2 evaluated colchicine 0.5 mg daily in patients with chronic coronary disease. Colchicine reduced the composite of cardiovascular death, spontaneous myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization (Nidorf et al., 2020). This trial strengthened the case for colchicine as an adjunct in selected stable coronary disease patients.

The mortality signal in LoDoCo2 requires careful wording. The trial reduced ischemic cardiovascular events, but it did not establish an all-cause mortality benefit. A numerical excess in non-cardiovascular death was observed, and its cause remains uncertain. Clinicians should disclose this uncertainty when discussing therapy with patients.

CIRT

CIRT tested low-dose methotrexate in patients with prior myocardial infarction or multivessel coronary disease plus diabetes or metabolic syndrome. Methotrexate did not reduce IL-1β, IL-6, hsCRP, or cardiovascular events (Ridker et al., 2019). The trial is an important corrective to simplistic thinking. Cardiovascular benefit cannot be assumed from a drug’s general anti-inflammatory effect.

CLEAR

The CLEAR trial added important nuance to the acute myocardial infarction setting. In patients with acute myocardial infarction, colchicine started soon after the event and continued for a median of approximately 3 years did not reduce the composite of cardiovascular death, recurrent myocardial infarction, stroke, or unplanned ischemia-driven coronary revascularization (Jolly et al., 2025). Diarrhea was more common with colchicine, while serious infection rates were not meaningfully different.

CLEAR does not erase the positive results of COLCOT and LoDoCo2, but it does make the clinical message more cautious. The most defensible position is that colchicine may be considered in selected patients with established atherosclerotic disease or high residual risk, rather than used reflexively after every acute coronary event.

Current Clinical Position

Low-dose colchicine is the most clinically relevant anti-inflammatory drug for cardiovascular prevention at present. In the United States, colchicine 0.5 mg once daily is FDA-labeled to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic disease or multiple cardiovascular risk factors. This indication does not mean that every patient with coronary disease should receive the drug. It means colchicine is a reasonable adjunct to consider when ischemic risk remains high and the safety profile is acceptable.

A practical candidate is a patient with established atherosclerotic cardiovascular disease who remains at elevated ischemic risk despite guideline-directed therapy and has no major contraindication or high-risk interaction. Examples may include selected patients with prior myocardial infarction, multivessel coronary disease, recurrent ischemic events, or chronic coronary disease with persistent residual risk.

hsCRP can help identify residual inflammatory risk, but it should not be used in isolation. A patient with elevated hsCRP may need evaluation for obesity, smoking, periodontal disease, chronic inflammatory disease, infection, renal disease, or other contributors. The clinician should treat the patient’s global risk, not the biomarker alone.

Safety, Contraindications, and Monitoring

Colchicine has a narrow therapeutic index. Gastrointestinal symptoms, especially new diarrhea, nausea, vomiting, abdominal cramping, or abdominal pain, may be early signs of toxicity. Severe toxicity can include myelosuppression, neuromuscular toxicity, rhabdomyolysis, multiorgan injury, and death.

Before prescribing colchicine, clinicians should review renal function, hepatic function, blood counts when clinically appropriate, and the full medication list. Colchicine should be avoided in patients with contraindications listed in current product labeling, including strong CYP3A4 or P-glycoprotein inhibitor use, renal failure, severe hepatic impairment, pre-existing blood dyscrasias, or hypersensitivity to the drug. Moderate CYP3A4 inhibitors, P-glycoprotein inhibitors, macrolides, azole antifungals, cyclosporine, verapamil, diltiazem, ranolazine, grapefruit products, statins, and fibrates require careful review because of toxicity or myopathy concerns.

Monitoring should be individualized. For lower-risk patients with stable kidney and liver function, periodic clinical reassessment and medication reconciliation may be sufficient. For older adults, patients with chronic kidney disease, hepatic impairment, neuromuscular symptoms, or substantial polypharmacy, periodic complete blood count, renal function, hepatic function, and symptom-triggered creatine kinase testing are reasonable. Patients should be advised to report severe gastrointestinal symptoms, muscle pain or weakness, numbness, paresthesias, dark urine, fever, bruising, or unusual bleeding.

Canakinumab requires a different safety framework because it is a biologic cytokine inhibitor. It is best discussed as proof-of-concept rather than routine cardiovascular prevention. Methotrexate should not be used for ASCVD event reduction in the absence of another established indication.

Practical Comparison of Anti-Inflammatory Strategies

Therapy or marker	Cardiovascular role	Key evidence	Practical limitation
Low-dose colchicine 0.5 mg daily	Adjunctive option in selected adults with established atherosclerotic disease or multiple risk factors	COLCOT and LoDoCo2 positive; CLEAR neutral in acute MI	Narrow therapeutic index, GI intolerance, interactions, renal/hepatic restrictions, uncertain mortality effect
Canakinumab	Mechanistic proof-of-concept for IL-1β inhibition	CANTOS positive in selected post-MI patients with hsCRP ≥2 mg/L	Infection risk, cost, not routine CV prevention
Methotrexate	No role for ASCVD event reduction without another indication	CIRT negative	Did not reduce IL-1β, IL-6, hsCRP, or CV events
hsCRP	Risk refinement and residual inflammatory-risk marker	Observational data, JUPITER, CANTOS selection	Nonspecific; should not be treated as a stand-alone indication

Relationship to Standard Cardiovascular Therapy

Anti-inflammatory therapy should complement, not replace, evidence-based prevention. LDL cholesterol and apolipoprotein B-containing lipoproteins remain causal drivers of atherosclerosis. Statins, ezetimibe, PCSK9-targeted therapies, bempedoic acid, antiplatelet therapy when indicated, blood pressure control, diabetes therapy, smoking cessation, exercise, and weight management remain foundational.

Colchicine is not an antiplatelet agent, anticoagulant, lipid-lowering drug, or antianginal therapy. Its role is residual-risk reduction in carefully selected patients. The decision to prescribe should be based on ischemic risk, competing risks, drug interactions, tolerability, renal and hepatic function, and patient preference.

References

Jolly, S. S., d’Entremont, M. A., Lee, S. F., et al. (2025). Colchicine in acute myocardial infarction. New England Journal of Medicine, 392, 633-642.

Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., et al. (2019). Atherosclerosis. Nature Reviews Disease Primers, 5(1), 56.

Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., et al. (2020). Colchicine in patients with chronic coronary disease. New England Journal of Medicine, 383(19), 1838-1847.

Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Jr., Kastelein, J. J. P., et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine, 359(21), 2195-2207.

Ridker, P. M., Everett, B. M., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Libby, P., et al. (2019). Anti-inflammatory therapy with low-dose methotrexate for the prevention of atherothrombotic events. New England Journal of Medicine, 380(8), 752-762.

Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., et al. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. New England Journal of Medicine, 377(12), 1119-1131.

Ross, R. (1999). Atherosclerosis: An inflammatory disease. New England Journal of Medicine, 340(2), 115-126.

Tardif, J. C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., et al. (2019). Efficacy and safety of low-dose colchicine after myocardial infarction. New England Journal of Medicine, 381(26), 2497-2505.

U.S. Food and Drug Administration. (2023). LODOCO (colchicine) tablets, for oral use: Prescribing information.

Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., et al. (2023). 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease. Circulation, 148, e9-e119.

Vrints, C., Andreotti, F., Koskinas, K. C., et al. (2024). 2024 ESC guidelines for the management of chronic coronary syndromes. European Heart Journal, 45, 3415-35.